|
Study Title
|
Contributing Institutes
|
Estimate of Costs by Institute ($)
|
Period of Study
|
Number of Subjects
|
|
Women's Health Trial: Feasibility Study in Minority Populations
|
NCI
NHLBI
NIDR
|
12,300,000
1,106,000
300,000
13,706,000
|
2 years
|
2,250
|
|
WHT Feasibility Study in Minority Populations: Salivary Study
|
NIDR (same as above)
|
300,000 (part of above)
|
2 years (same as above period)
|
200 (part of above sample)
|
|
Postmenopausal Estrogen/Progestin Interventions (PEPI)
|
NHLBI
NICHD
NIAMS
NIA
NIDDK
|
15,187,000
3,535,355
2,025,000
578,000
535,000
21,860,355
|
10 years
|
875
|
|
Breast Cancer Prevention Trial - Tamoxifen
|
NCI
NHLBI
NIAMS
|
65,820,000
7,931,000
2,136,000
75,887,000
|
7 years
|
16,000
|
|
Study of Osteoporotic Fractures
|
NIAMS
NIA
|
32,489,000
14,615,191
47,104,191
|
11 years
|
9,700
|
|
Efficacy of Estrogen in Hyperprolactinemic Amenorrhea
|
NIDDK
ORWH
|
1,043,032
NA
1,043,032
|
5 years
|
100
|
|
Membrous Lupus Nephropathy
|
NIDDK
NCI
|
1,257,000
NA
1,257,000
|
9 years
|
16 to date (75% female)
|
|
Combination Radioiodine and Adriamycin for Follicular Thyroid Carcinoma
|
NIDDK
NCI
|
1,499,000
NA
1,499,000
|
6 years
|
22 to date (75% female)
|
|
Vitamin E, Betacarotene and Aspirin in Women
|
NCI
NHLBI
|
8,474,728
8,348,000
16,822,728
|
5 years
|
40,000
|
|
Long-Term Outcome of Obesity Treatment in Minority Women
|
NIDDK
ORMH
|
3,534,011
|
6 years
|
600
|
